SVT 1B149
Alternative Names: SVT-1B149Latest Information Update: 28 Apr 2024
At a glance
- Originator Servatus Biopharmaceuticals
- Class Bacteria; Gastrokinetics; Irritable bowel syndrome therapies
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Constipation; Irritable bowel syndrome
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Constipation in Australia (PO)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in Australia (PO)
- 17 Jan 2022 Servatus Biopharmaceuticals plans a phase II trial for Irritable Bowel Syndrome and Constipation (Servatus Biopharmaceuticals pipeline, January 2022)